EC Number   |
Application |
Reference |
|---|
   3.4.17.23 | medicine |
17-beta-estradiol may reduce SARS-CoV-2 infection of lung epithelial cells |
764554 |
| 3.4.17.23 | drug development |
a super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection |
763700 |
| 3.4.17.23 | pharmacology |
ACE 2 is a potential therapeutic target in the treatment of heart failure |
708649 |
| 3.4.17.23 | medicine |
ACE-2 protects against lung fibrogenesis by limiting the local accumulation of the profibrotic peptide angiotensin II |
677486 |
| 3.4.17.23 | medicine |
ACE2 activators are a reliable approach which could lead to the development of a novel class of antihypertensive and cardioprotective drugs |
693702 |
| 3.4.17.23 | medicine |
ACE2 is a functional receptor for the causative agent of severe acute repiratory syndrome, the SARS coronavirus, ACE2 also plays a role in the development of liver fibrosis and subsequent cirrhosis |
678102 |
| 3.4.17.23 | medicine |
ACE2 is a key factor for protection from ARDS/acute lung injury and it functions as a critical SARS receptor in vivo, recombinant ACE2 protein might not only be a treatment to block spreading of SARS but also to protect SARS patients from developing lung failure |
679135 |
| 3.4.17.23 | diagnostics |
ACE2 levels is a putative early biomarker of SARS-CoV-2 infection severity |
763771 |
| 3.4.17.23 | medicine |
ACE2 may be a target for therapeutic interventions that aim to reduce albuminuria and glomerular injury |
680388 |
| 3.4.17.23 | pharmacology |
ACE2 might be a target for treatment of non-small cell lung cancer |
710171 |
